Anondita Medicare Limited reported a strong financial performance for FY26, with revenue from operations increasing 78% year-on-year to ₹137.42 Cr. The company’s profit after tax (PAT) surged 107% to ₹34.30 Cr, while EBITDA grew 99% to ₹31.90 Cr. The growth was attributed to operational efficiency, a better product mix, and scale benefits, alongside successful expansion into international markets. Management expressed confidence in achieving a revenue target of ₹1,000 Cr within the next two years, driven by new capacity and global contracts.

The momentum continued into the second half of the fiscal year, with H2 FY26 revenue growing 82.77% YoY to ₹83.32 Cr. EBITDA for the half-year increased 99% to ₹31.89 Cr, and PAT rose 103% to ₹21.28 Cr. PAT margins improved to 25.54% during this period. The company operates 15 production lines with an annual capacity of approximately 806 million condoms, following a recent expansion from 562 million units.

Operational Highlights and Strategic Developments

FY26 was a transformational year for the manufacturer of condoms and sexual wellness products. The company successfully completed its IPO listing on the NSE SME platform and achieved several certifications, including MDSAP and SABS. Strategic vendor registrations were completed in Brazil and South Africa to cater to rising demand, with opportunities also emerging in Nepal, Uzbekistan, Cuba, Kenya, and the UAE.

A key milestone was the successful trial production of female condoms, a segment the company believes offers significant long-term growth potential due to increasing healthcare awareness and limited global manufacturing capacities. Anondita Medicare is the world's first company to register in Brazil for the supply of both female latex and non-latex condoms. The distribution network for the COBRA brand was also strengthened across 8 states, covering 4,569 retailers.

Future Outlook and Expansion Plans

Management outlined a roadmap to scale revenue to ₹1,000 Cr in two years, focusing on exports and female condoms. The company expects to secure a significant portion of the South African government tender, which requires 1 billion pieces annually over five years. Additionally, the firm aims to increase female condom capacity to 240 million pieces annually.

The company has invested ₹62 Cr in capex, with ₹24 Cr already spent to expand capacity by 307 million units. A further expansion of 250 million units is underway under work-in-progress, expected to add ₹325 Cr to turnover. Management highlighted that in-house patented machinery and packaging capabilities would drive margin improvements.

Financial Performance Summary

The company remains confident about sustaining its growth momentum, citing strong sector tailwinds, improving scale, and growing export opportunities.

Anondita Medicare Limited shareholders have approved all seven resolutions placed before the Extra-Ordinary General Meeting (EGM) held on May 28, 2026. The meeting, conducted via Video Conference, saw the passage of special and ordinary resolutions concerning capital raising, related party transactions, and managerial remuneration.

The scrutinizer's report submitted by Mr. Mohit Singhal, Practicing Company Secretary, confirmed that the resolutions were passed with the requisite majority. The key agenda items included the issue of warrants convertible into equity shares to persons belonging to the promoter category on a preferential basis. Shareholders also approved material related party transactions with Anondita Healthcare & Rubber Products (India) Limited and Mr. Anupam Ghosh for the financial year 2026-27, alongside the ratification of prior transactions with the former entity.

Voting Outcomes

The voting results indicated strong support for the management's proposals. For the special resolution regarding the issuance of warrants, 11 members cast 11,372,595 votes in favour, representing 100% of the votes polled. Similarly, the special resolution to amend the main object clause of the Memorandum of Association received 11,372,595 votes in favour, also constituting 100% of the votes polled.

Resolutions concerning managerial remuneration for Mr. Reshant Ghosh, Whole Time Director, and Mr. Anupam Ghosh, Managing Director, were passed with identical margins. Each of these special resolutions secured 11,372,595 votes in favour.

Related Party Transactions

Three ordinary resolutions related to related party transactions were approved with 100% assent from eligible voters. Promoters were ineligible to vote on these resolutions pursuant to Regulation 23(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Consequently, the votes were cast by nine eligible members, totalling 116,002 votes in favour for each resolution.

The table below summarizes the voting results for the key resolutions:

The remote e-voting process was managed by National Securities Depository Limited (NSDL), with the platform open from May 25 to May 27, 2026. A total of 11 members participated in the e-voting process.